Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a ‘milestone payment’ from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: ‘The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients.’

Current stock price: 184.95 pence, up 1.3%

12-month change: down 25%

Copyright 2023 Alliance News Ltd. All Rights Reserved.